Harjasleen K Walia, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 5 carriers
- Office
- 1
Offices
1 location
Hospitals listed: 058354 · El Camino Health. That is not proof they admit you there this week.
Plans that list them
25 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Walia’s office at (408) 706-5500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A158682 · Current
Licensed to practise in California · since 2018 · expires 2028-09-30 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$153,125
Medicare paid this office $153,125 for 122 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 15 | $57,007 | None |
| Long return visit (40+ min) | 106 | $52,365 | $160 |
| New patient visit (60+ min) | 45 | $9,345 | $208 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 90 | $5,877 | $29 |
| Evaluation of neuropsychological test, first hour | 30 | $3,569 | $119 |
See all 13 services
| Botox | 15 | $57,007 | None |
| Long return visit (40+ min) | 106 | $52,365 | $160 |
| New patient visit (60+ min) | 45 | $9,345 | $208 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 90 | $5,877 | $29 |
| Evaluation of neuropsychological test, first hour | 30 | $3,569 | $119 |
| Test for abnormal eye movement using a rotating chair | 23 | $3,352 | $146 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,468 | $123 |
| Evaluation and testing for balance with recording | 23 | $2,437 | $106 |
| Face injection for nerve paralysis | 11 | $2,012 | $155 |
| Administration of psychological or neuropsychological test, first 30 minutes | 31 | $1,448 | $41 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 32 | $1,366 | $38 |
| Test for balance and posture | 25 | $1,153 | $46 |
| Test to assess balance during warm and cool irrigation in both ears | 20 | $776 | $39 |
Who their Medicare patients are
122 Original Medicare patients in 2024. Average age 76 · Women 58% · Health risk score 1.28. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Depression 43% · Stroke 35% · Coronary heart disease 28% · Cancer 26% · Diabetes 20% · Chronic kidney disease 20% · Dementia 20% · Atrial fibrillation 17% · Heart failure 15% · COPD 13%.
The office billed $1,044,555, Medicare allowed $197,509 and paid $153,125; for 12,448 services of 41 kinds; $57,018 of it was for drugs given in the office and $96,107 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 122 | 12,448 | 76 | 1.28 | $1,044,555 | $153,125 |
| 2023 | 117 | 5,860 | 77 | 1.29 | $712,087 | $102,956 |
| 2022 | 82 | 5,573 | 76 | 1.21 | $419,841 | $85,277 |
| 2021 | 74 | 5,589 | 75 | 1.15 | $243,683 | $66,334 |
| 2020 | 120 | 3,018 | 76 | 1.40 | $71,930 | $42,440 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 99 | $39,109 | $149 |
| New patient visit (60+ min) | 53 | $10,158 | $192 |
| Test for abnormal eye movement using a rotating chair | 32 | $4,321 | $135 |
| Evaluation and testing for balance with recording | 31 | $3,012 | $97 |
| Evaluation of neuropsychological test, first hour | 27 | $2,958 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,952 | $103 |
| Test for balance and posture | 30 | $1,394 | $46 |
| Administration of psychological or neuropsychological test, first 30 minutes | 28 | $1,179 | $42 |
| Test to assess balance during warm and cool irrigation in both ears | 32 | $1,144 | $36 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 26 | $1,023 | $39 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $500 | $29 |
2022: 8 services
| Long return visit (40+ min) | 69 | $33,045 | $161 |
| New patient visit (45+ min) | 28 | $4,215 | $151 |
| New patient visit (60+ min) | 18 | $3,699 | $205 |
| Evaluation of neuropsychological test, first hour | 16 | $2,147 | $113 |
| Return visit (30+ min) | 18 | $2,066 | $103 |
| Short return visit (20+ min) | 14 | $1,835 | $76 |
| Administration of psychological or neuropsychological test, first 30 minutes | 17 | $745 | $44 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 13 | $520 | $40 |
2021: 3 services
| Long return visit (40+ min) | 61 | $16,842 | $164 |
| Return visit (30+ min) | 41 | $9,449 | $124 |
| New patient visit (45+ min) | 21 | $3,344 | $159 |
2020: 6 services
| Long return visit (40+ min) | 95 | $17,633 | $140 |
| Botox | 12 | $13,644 | None |
| New patient visit (60+ min) | 19 | $3,758 | $198 |
| Return visit (30+ min) | 21 | $2,432 | $106 |
| Face injection for nerve paralysis | 12 | $1,849 | $132 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,375 | $106 |
Drugs they prescribed that Part D paid
$144,714
Pharmacies billed $144,714 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 791) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
679 generic and 112 brand-name prescriptions · $144,714 in drug cost · 26 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nurtec Odt | None | 22 | $30,801 | $1,400 |
| Ubrelvy | None | 21 | $27,516 | $1,310 |
| Ajovy | None | 22 | $20,779 | $945 |
| Emgality | Migraine | 14 | $10,850 | $775 |
| Ajovy | None | 11 | $7,540 | $685 |
See all 23 drugs
| Nurtec Odt | None | 22 | $30,801 | $1,400 |
| Ubrelvy | None | 21 | $27,516 | $1,310 |
| Ajovy | None | 22 | $20,779 | $945 |
| Emgality | Migraine | 14 | $10,850 | $775 |
| Ajovy | None | 11 | $7,540 | $685 |
| Zolmitriptan | None | 22 | $4,137 | $188 |
| Memantine | None | 113 | $2,793 | $25 |
| Carbidopa-Levodopa | None | 60 | $2,100 | $35 |
| Carbidopa-Levodopa Er | None | 19 | $1,620 | $85 |
| Duloxetine | None | 14 | $1,443 | $103 |
| Ondansetron Odt | None | 14 | $1,370 | $98 |
| Gabapentin | None | 63 | $1,294 | $21 |
| Venlafaxine | None | 24 | $498 | $21 |
| Nortriptyline | None | 33 | $460 | $14 |
| Levetiracetam | None | 23 | $444 | $19 |
| Fluoxetine | None | 11 | $359 | $33 |
| Quetiapine | None | 26 | $338 | $13 |
| Donepezil | None | 25 | $320 | $13 |
| Baclofen | None | 33 | $291 | $9 |
| Sumatriptan | None | 14 | $272 | $19 |
| Escitalopram | None | 11 | $210 | $19 |
| Paroxetine | None | 13 | $122 | $9 |
| Sertraline | None | 12 | $13 | $1 |
Year by year
| 2024 | 791 | 129 | 0% (0) | 14% | $144,714 |
| 2023 | 662 | 102 | 0% (0) | 10% | $81,268 |
| 2022 | 452 | 74 | 0% (0) | 10% | $75,739 |
| 2021 | 307 | 66 | 0% (0) | 11% | $56,805 |
| 2020 | 194 | 72 | 0% (0) | None | $8,084 |
| 2019 | 351 | 86 | 0% (0) | 6% | $26,663 |
| 2018 | 171 | 63 | 0% (0) | 13% | $16,972 |
| 2017 | 144 | 57 | 0% (0) | 15% | $16,232 |
| 2016 | 24 | None | 0% (0) | None | $990 |
| 2015 | 115 | 27 | 0% (0) | 23% | $5,978 |
| 2014 | 59 | 11 | 0% (0) | None | $1,307 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Nurtec Odt | None | 14 | $15,841 | $1,132 |
| Emgality | Migraine | 17 | $14,964 | $880 |
| Ajovy | None | 20 | $13,355 | $668 |
| Ubrelvy | None | 11 | $10,876 | $989 |
| Memantine | None | 100 | $6,487 | $65 |
| Carbidopa-Levodopa | None | 71 | $3,422 | $48 |
| Gabapentin | None | 75 | $1,697 | $23 |
| Carbidopa-Levodopa Er | None | 14 | $1,219 | $87 |
| Quetiapine | None | 39 | $1,080 | $28 |
| Sumatriptan | None | 16 | $735 | $46 |
| Venlafaxine | None | 11 | $657 | $60 |
| Levetiracetam | None | 22 | $630 | $29 |
| Nortriptyline | None | 24 | $509 | $21 |
| Donepezil | None | 31 | $462 | $15 |
| Baclofen | None | 21 | $232 | $11 |
| Simvastatin | None | 12 | $166 | $14 |
| Methocarbamol | None | 16 | $118 | $7 |
2022: 12 drugs
| Emgality | Migraine | 15 | $10,457 | $697 |
| Amantadine | None | 14 | $2,426 | $173 |
| Gabapentin | None | 91 | $2,308 | $25 |
| Memantine | None | 46 | $2,098 | $46 |
| Carbidopa-Levodopa | None | 48 | $2,015 | $42 |
| Quetiapine | None | 19 | $1,257 | $66 |
| Nortriptyline | None | 35 | $458 | $13 |
| Levetiracetam | None | 14 | $436 | $31 |
| Carbidopa-Levodopa Er | None | 11 | $414 | $38 |
| Baclofen | None | 17 | $299 | $18 |
| Verapamil | None | 13 | $89 | $7 |
| Methocarbamol | None | 12 | $42 | $4 |
2021: 6 drugs
| Cambia | 15 | $11,909 | $794 |
| Gabapentin | 105 | $2,094 | $20 |
| Amantadine | 16 | $896 | $56 |
| Nortriptyline | 16 | $475 | $30 |
| Carbidopa-Levodopa | 16 | $404 | $25 |
| Venlafaxine | 11 | $242 | $22 |
2020: 4 drugs
| Gabapentin | 28 | $753 | $27 |
| Carbidopa-Levodopa | 13 | $517 | $40 |
| Nortriptyline | 14 | $272 | $19 |
| Rizatriptan | 12 | $168 | $14 |
2019: 10 drugs
| Butalbital-Acetaminophen-Caffe | 16 | $2,154 | $135 |
| Diclofenac | 29 | $2,101 | $72 |
| Gabapentin | 43 | $762 | $18 |
| Levetiracetam | 14 | $479 | $34 |
| Ondansetron Odt | 24 | $446 | $19 |
| Verapamil | 18 | $404 | $22 |
| Rizatriptan | 26 | $337 | $13 |
| Naratriptan | 16 | $260 | $16 |
| Nortriptyline | 18 | $226 | $13 |
| Ondansetron | 11 | $86 | $8 |
2018: 4 drugs
| Sumatriptan | 31 | $6,846 | $221 |
| Topiramate | 23 | $643 | $28 |
| Gabapentin | 20 | $384 | $19 |
| Carbidopa-Levodopa | 12 | $172 | $14 |
2017: 2 drugs
| Sumatriptan | 16 | $3,487 | $218 |
| Gabapentin | 13 | $184 | $14 |
2015: 2 drugs
| Propranolol Hcl Er | 11 | $461 | $42 |
| Atorvastatin | 18 | $354 | $20 |
Money from drug and device companies
$1,191 in 2025
| 2025 | 9 | 43 | None | $1,191 |
| 2024 | 9 | 41 | None | $907 |
| 2023 | 10 | 69 | None | $1,258 |
| 2022 | 13 | 56 | None | $1,340 |
| 2021 | 14 | 58 | None | $1,191 |
| 2020 | 14 | 43 | None | $948 |
| 2019 | 2 | 2 | None | $165 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lundbeck | Vyepti | $251 | 10 payments
|
| Axsome Therapeutics | Symbravo | $217 | 4 payments
|
| Pfizer | Nurtec Odt | $168 | 8 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $158 | 5 payments
|
| Abbvie | Qulipta | $143 | 7 payments
|
| Eisai | Leqembi | $133 | 5 payments
|
See all 43 published payments
| Axsome Therapeutics | Meals · 2025-12-24 | Symbravo | $17 |
| Abbvie | Meals · 2025-12-18 | Qulipta | $26 |
| Lundbeck | Meals · 2025-12-09 | Vyepti | $33 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-03 | Dysport | $25 |
| Abbvie | Meals · 2025-12-02 | Ubrelvy | $8 |
| Abbvie | Meals · 2025-11-24 | Qulipta | $8 |
| Abbvie | Meals · 2025-11-12 | Qulipta | $29 |
| Eisai | Meals · 2025-11-10 | Leqembi | $25 |
| Lundbeck | Meals · 2025-11-05 | Vyepti | $34 |
| Teva Pharmaceuticals USA | Meals · 2025-10-29 | Austedo Xr | $36 |
| Axsome Therapeutics | Meals · 2025-10-13 | Symbravo | $23 |
| Eisai | Meals · 2025-10-08 | Leqembi | $22 |
| Lundbeck | Meals · 2025-10-01 | Vyepti | $32 |
| Pfizer | Meals · 2025-09-03 | Nurtec Odt | $28 |
| Axsome Therapeutics | Meals · 2025-08-20 | Symbravo | $31 |
| Lundbeck | Meals · 2025-08-19 | Vyepti | $22 |
| Teva Pharmaceuticals USA | Meals · 2025-08-13 | Austedo Xr | $33 |
| Lundbeck | Meals · 2025-08-07 | Vyepti | $22 |
| Lundbeck | Meals · 2025-08-07 | Vyepti | $3 |
| Abbvie | Meals · 2025-07-29 | Qulipta | $28 |
| Pfizer | Meals · 2025-07-16 | Nurtec Odt | $27 |
| Lilly USA | Meals · 2025-07-09 | Kisunla | $30 |
| Merz Pharmaceuticals | Meals · 2025-07-07 | Xeomin | $33 |
| Abbvie | Meals · 2025-06-26 | Botox | $23 |
| Eisai | Meals · 2025-06-23 | Leqembi | $28 |
| Axsome Therapeutics | Meals · 2025-06-19 | Symbravo | $145 |
| Pfizer | Meals · 2025-06-11 | Nurtec Odt | $27 |
| Teva Pharmaceuticals USA | Meals · 2025-06-09 | Ajovy | $26 |
| Lundbeck | Meals · 2025-06-02 | Vyepti | $25 |
| Lilly USA | Meals · 2025-05-06 | Amyvid | $34 |
| Lundbeck | Meals · 2025-04-23 | Vyepti | $22 |
| Teva Pharmaceuticals USA | Meals · 2025-04-21 | Ajovy | $34 |
| Pfizer | Meals · 2025-04-16 | Zavzpret | $14 |
| Pfizer | Meals · 2025-04-09 | Nurtec Odt | $29 |
| Eisai | Meals · 2025-04-02 | Leqembi | $30 |
| Lundbeck | Meals · 2025-03-18 | Vyepti | $34 |
| Teva Pharmaceuticals USA | Meals · 2025-02-19 | Austedo Xr | $29 |
| Abbvie | Meals · 2025-02-18 | Qulipta | $22 |
| Pfizer | Meals · 2025-02-05 | Nurtec Odt | $27 |
| Lundbeck | Meals · 2025-02-04 | Vyepti | $25 |
| Eisai | Meals · 2025-01-27 | Leqembi | $28 |
| Pfizer | Meals · 2025-01-13 | Zavzpret | $2 |
| Pfizer | Meals · 2025-01-13 | Zavzpret | $12 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $907
| Abbvie | Ubrelvy | $206 | 9 payments
|
| Pfizer | Nurtec Odt | $139 | 7 payments
|
| Lundbeck | Vyepti | $137 | 7 payments
|
| SK Life Science | None | $104 | 4 payments
|
| Eisai | Leqembi | $101 | 5 payments
|
| Teva Pharmaceuticals USA | Ajovy | $89 | 3 payments
|
| Lilly USA | Amyvid | $56 | 2 payments
|
| Scilex Pharmaceuticals | Elyxyb - Celecoxib | $39 | 2 payments
|
| Acorda Therapeutics | Inbrija | $36 | 2 payments
|
2023: $1,258
| Impel Pharmaceuticals | Trudhesa | $249 | 20 payments
|
| AbbVie | Qulipta | $230 | 10 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $174 | 9 payments
|
| Lundbeck | Vyepti | $162 | 9 payments
|
| Acorda Therapeutics | Inbrija | $112 | 6 payments
|
| Pfizer | Nurtec Odt | $104 | 5 payments
|
| Biogen | Tysabri | $96 | 4 payments
|
| Lilly USA | Amyvid | $83 | 4 payments
|
| Eisai | Leqembi | $25 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido | $24 | 1 payment
|
2022: $1,340
| Teva Pharmaceuticals USA | Austedo | $224 | 8 payments
|
| Impel Pharmaceuticals | Trudhesa | $224 | 8 payments
|
| Abbvie | Botox | $177 | 11 payments
|
| Abbott Laboratories | Proclaim | $156 | 1 payment
|
| Janssen Pharmaceuticals | Ponvory | $141 | 2 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $136 | 12 payments
|
| Lundbeck | Vyepti | $106 | 5 payments
|
| Eisai | Fycompa | $59 | 3 payments
|
| Lilly USA | Amyvid | $52 | 2 payments
|
| Genentech USA | Ocrevus | $18 | 1 payment
|
| Amgen | Aimovig | $17 | 1 payment
|
| Allergan | Botox | $15 | 1 payment
|
| Biogen | Tysabri | $14 | 1 payment
|
2021: $1,191
| AbbVie | Ubrelvy | $293 | 11 payments
|
| Teva Pharmaceuticals USA | Ajovy | $232 | 9 payments
|
| Allergan | Botox | $181 | 14 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $83 | 4 payments
|
| Amgen | Aimovig | $75 | 3 payments
|
| Eisai | Fycompa | $74 | 3 payments
|
| Kyowa Kirin | Nourianz | $64 | 4 payments
|
| SK Life Science | None | $43 | 2 payments
|
| Lilly USA | Emgality | $40 | 2 payments
|
| Lundbeck | Vyepti | $33 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $23 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $20 | 1 payment
|
| Chiesi USA | Cleviprex | $18 | 1 payment
|
| Biogen | None | $13 | 1 payment
|
2020: $948
| Allergan | Botox | $201 | 11 payments
|
| Amgen | Aimovig | $148 | 2 payments
|
| Eisai | Fycompa | $123 | 7 payments
|
| Alexion Pharmaceuticals | Soliris | $115 | 6 payments
|
| Biogen | Vumerity | $49 | 2 payments
|
| SK Life Science | None | $48 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $48 | 2 payments
|
| Lilly USA | Emgality | $45 | 2 payments
|
| Kyowa Kirin | Nourianz | $45 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $42 | 2 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $29 | 1 payment
|
| US WorldMeds | Xadago | $23 | 1 payment
|
| Chiesi USA | Cleviprex 50mg/100ml | $17 | 1 payment
|
| Lundbeck | Vyepti | $14 | 1 payment
|
2019: $165
| Allergan | Botox | $134 | 1 payment
|
| Amgen | Aimovig | $31 | 1 payment
|
Professional record
- NPI
- 1356786495
- Licence
- CA A158682California A158682: Current · expires 2028-09-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 2440 Samaritan Dr Ste 2, San Jose, CA, 95124
- NPI first listed
- 2013-05-02
- NPI last updated
- 2022-04-24
- NPI record certified
- 2021-05-12
This is when the NPI record was last certified, not a medical board exam.